Skip to main content
. Author manuscript; available in PMC: 2012 Sep 23.
Published in final edited form as: Differentiation. 2010 Jun 19;80(2-3):140–146. doi: 10.1016/j.diff.2010.05.006

Fig. 1.

Fig. 1

AGPAT1 downregulation inhibits myogenesis in C2C12 cells. (A) changes in AGPAT mRNA levels in C2C12 cells 48 h following treatment with non-targeting (NT), AGPAT1 or AGPAT2 siRNA. Expression levels were normalized to 18s mRNA levels. (B) MF-20 immunostaining of C2C12 cells at day 0 and after 4 days of differentiation in 2% horse serum following treatment with NT, AGPAT1 or AGPAT2 siRNA. Right panels show DAPI staining of nuclei. Representative images of three independent experiments are shown. Magnification 20×. (C) Levels of myogenesis related genes after 48 h of differentiation following treatment with NT or AGPAT siRNA. Values are the mean of three independent determinations ± S.D.*p < 0.05, **p < 0.01 (D and E) MF-20 immunostaining. Magnification 20×. (D) or fusion index (E) of C2C12 cells after NT or AGPAT1 siRNA treatment followed by rescue with empty vector, V5-AGPAT1 or V5-AGPAT2. (F) AGPAT1 or MF-20 protein levels during myogenesis. β-actin was used as a loading control.